RGEN - Repligen Corporation
NEXT EARNINGS:
May 5, 2026
EPS Est: $0.46
|
Rev Est: $192.1M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$181.43
DETAILS
HIGH:
$205.00
LOW:
$150.00
MEDIAN:
$190.00
CONSENSUS:
$181.43
UPSIDE:
34.72%
Market Cap:
7.58B
Volume:
2,214,095
Avg Volume:
672,853
52 Week Range:
102.97-175.77
Sector:
Healthcare
Industry:
Medical - Instruments & Supplies
Beta:
1.13
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
1,778
IPO Date:
1986-04-29
EPS (TTM):
0.87
P/E Ratio:
188.46
Revenue (TTM):
738.26M
Total Assets:
2.95B
Total Debt:
689.95M
Cash & Equiv:
566.02M
Rev Growth (5Y):
15.1%
EPS Growth (5Y):
-5.3%
FCF Growth (5Y):
21.0%
ROCE:
N/A
Debt/Equity:
0.33
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-24 | $0.23 | $0.44 | -47.7% | $197.9M | $191.8M | +3.2% |
| 2025-10-28 | $0.46 | $0.42 | +9.5% | $188.8M | $192.2M | -1.8% |
| 2025-07-29 | $0.37 | $0.40 | -7.5% | $182.4M | $181.8M | +0.3% |
| 2025-04-29 | $0.39 | $0.35 | +11.4% | $169.2M | $173.6M | -2.5% |
| 2025-02-20 | $0.44 | $0.41 | +7.3% | $167.5M | $164.1M | +2.1% |
| 2024-11-12 | $0.43 | $0.34 | +28.2% | $154.9M | $153.0M | +1.2% |
| 2024-07-30 | $0.33 | $0.33 | 0.0% | $154.1M | $154.1M | 0.0% |
| 2024-05-01 | $0.28 | $0.29 | -3.4% | $151.3M | $150.1M | +0.9% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 738.26M | 634.44M | 632.36M | 801.54M | 670.53M | 366.26M | 270.25M | 194.03M | 141.24M | 104.54M | 83.54M | 63.55M |
| Net Income | 48.89M | (25.51M) | 35.60M | 185.96M | 128.29M | 59.93M | 21.41M | 16.62M | 28.35M | 11.68M | 9.35M | 8.17M |
| EPS | 0.87 | -0.46 | 0.64 | 3.35 | 2.33 | 1.14 | 0.44 | 0.38 | 0.74 | 0.35 | 0.28 | 0.25 |
| Total Assets | 2.95B | 2.83B | 2.83B | 2.53B | 2.36B | 1.90B | 1.40B | 139.45M | 120.41M | 288.91M | 146.24M | (65.43M) |
| Total Debt | 689.95M | 686.25M | 711.80M | 422.96M | 366.05M | 275.42M | 263.32M | 103.49M | 99.25M | 95.27M | 0 | 0 |
| Cash & Equivalents | 566.02M | 757.36M | 751.32M | 523.46M | 603.81M | 717.29M | 528.39M | 193.82M | 173.76M | 141.78M | 73.41M | 62.00M |
| Operating Cash Flow | 117.42M | 175.39M | 113.92M | 172.08M | 119.02M | 62.62M | 67.22M | 32.77M | 17.45M | 7.52M | 15.05M | 18.40M |
| Free Cash Flow | 93.90M | 142.49M | 74.93M | 38.74M | 47.74M | 36.28M | 44.06M | 18.73M | 12.00M | 3.20M | 12.43M | 12.80M |
| FCF per Share | 1.67 | 2.55 | 1.34 | 0.70 | 0.87 | 0.69 | 0.91 | 0.43 | 0.31 | 0.10 | 0.38 | 0.39 |
| Book Value | 2.11B | 1.97B | 1.96B | 1.91B | 1.75B | 1.53B | 1.06B | 615.57M | 591.55M | 168.76M | 122.75M | 111.73M |
| Cash & ST Investments | 767.63M | 757.36M | 751.32M | 623.76M | 603.81M | 717.29M | 528.39M | 193.82M | 173.76M | 141.78M | 73.41M | 62.00M |
| ROC Equity | 0.02 | -0.01 | 0.02 | 0.10 | 0.07 | 0.04 | 0.02 | 0.03 | 0.05 | 0.07 | 0.08 | 0.07 |